AR088423A1 - Ligadores p1 ciclicos como inhibidores del factor xia - Google Patents

Ligadores p1 ciclicos como inhibidores del factor xia

Info

Publication number
AR088423A1
AR088423A1 ARP120102879A ARP120102879A AR088423A1 AR 088423 A1 AR088423 A1 AR 088423A1 AR P120102879 A ARP120102879 A AR P120102879A AR P120102879 A ARP120102879 A AR P120102879A AR 088423 A1 AR088423 A1 AR 088423A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
nr9c
alkylene
halogen
Prior art date
Application number
ARP120102879A
Other languages
English (en)
Inventor
y s lam Patrick
G Clark Charles
R Corte James
R Ewing William
J Gilligan Paul
Jeon Yoon
Yang Wu
M Ii Smith Leon
Wang Yufeng
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR088423A1 publication Critical patent/AR088423A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Abstract

Estos compuestos son inhibidores selectivos del factor Xla o inhibidores duales de FXIa y calicreína plasmática. También, composiciones farmacéuticas que comprenden estos compuestos y métodos para tratar trastornos tromboembólicos y/o inflamatorios mediante su uso. Reivindicación 1: Un compuesto de la fórmula (1) o un estereoisómero, un tautómero, una sal aceptable desde el punto de vista farmacéutico, un solvato de este, en donde: G¹ se selecciona del grupo que consiste en un arilo de 6 miembros y un heteroarilo de 5 a 6 miembros, en donde el arilo y el heteroarilo se sustituyen con 1 - 5 R⁸; el anillo A se selecciona del grupo que consiste en un arilo de 6 miembros y un heterociclo de 5 a 6 miembros, en donde el arilo y el heterociclo se sustituyen con 1 - 3 R¹³; X se selecciona del grupo que consiste en alquileno C₄₋₈ y alquenileno C₄₋₈, en donde el alquileno y el alquenileno se sustituyen con R¹, R² y R⁶; de manera alternativa, uno o más de los átomos de carbono del alquileno y alquenileno se pueden reemplazar por O, C=O, S(O)ₚ, NH y N(alquilo C₁₋₄); X² se selecciona del grupo que consiste en CHR¹¹, C=O, O, NH y N(alquilo C₁₋₄); X³ es CR¹² o N; siempre que X³ sea CR¹² cuando X² es O, NH o N(alquilo C₁₋₄); R¹ y R² se seleccionan independientemente del grupo que consiste en H, halógeno, alquilo C₁₋₆, OH, NH₂, -CH₂NH₂, haloalquilo C₁₋₄, -OCH₂F, -OCHF₂, -OCF₃, NH(alquilo C₁₋₄), N(alquilo C₁₋₄)₂, alcoxi C₁₋₄, -CH₂OH y -CH₂O(alquilo C₁₋₄); de manera alternativa, R¹ y R² se toman en forma conjunta con los átomos de carbono a los que están unidos para formar un carbociclo; R³ se selecciona del grupo que consiste en H, haloalquilo, -C(=O)OH, -C(=O)O-alquilo C₁₋₄ y -C(=O)NR⁹R¹⁰; R⁴ se selecciona del grupo que consiste en H y alquilo C₁₋₆; de manera alternativa, R³ y R⁴ son, en forma conjunta, =O; R⁵ se selecciona independientemente del grupo que consiste en H, halógeno, alquilo C₁₋₄, OH, CN, NR⁹R¹⁰, NO₂, alcoxi C₁₋₄, -C(=O)OH, -C(=O)O(alquilo C₁₋₄), -C(=O)NH₂, C(=O)NR⁹(alquilo C₁₋₄), -C(=O)NR⁹-alquilen C₁₋₄-O(alquilo C₁₋₄), -NR⁹C(=O)alquilo C₁₋₄, -NR⁹C(=O)O-alquilo C₁₋₄, -NR⁹C(=O)alquilen C₁₋₄-O(alquilo C₁₋₄), -NR⁹C(=O)O-alquilen C₁₋₄-O(alquilo C₁₋₄), -NR⁹C(=O)NH(alquilo C₁₋₄), R¹⁵, -C(=O)OR¹⁵, -C(=O)NR⁹R¹⁵, -NR⁹R¹⁵, -NR⁹C(=O)R¹⁵ y -NR⁹C(=O)OR¹⁵; R⁵ᵃ se selecciona del grupo que consiste en H, halógeno y metilo; R⁶ se selecciona del grupo que consiste en H, alquilo C₁₋₆ y OH; R⁷ se selecciona del grupo que consiste en H, ²H, F, =O, OH y alquilo C₁₋₄; R⁸ se selecciona del grupo que consiste en H, halógeno, OH, CN, alquilo C₁₋₆, haloalquilo, alcoxi, haloalcoxi y -C(=O)alquilo C₁₋₃; R⁹ se selecciona del grupo que consiste en H y alquilo C₁₋₆; R¹⁰ se selecciona del grupo que consiste en H y alquilo C₁₋₆; de manera alternativa, R⁹ y R¹⁰ se toman en forma conjunta con el átomo de nitrógeno al que están unidos para formar un heterociclo de 4- a 7- miembros sustituido con R¹⁴; R¹¹ se selecciona del grupo que consiste en H y alquilo C₁₋₆; R¹² se selecciona del grupo que consiste en H, ²H y alquilo C₁₋₆; R¹³ se selecciona del grupo que consiste en H, OH, halógeno, CN, alquilo C₁₋₆, alcoxi, haloalquilo, haloalcoxi y cicloalquilo C₃₋₆; R¹⁴ se selecciona del grupo que consiste en H, OH, halógeno y alquilo C₁₋₆; R¹⁵ se selecciona del grupo que consiste en: -(CH₂)ₙ-carbociclo C₃₋₁₀ y -(CH₂)ₙ-heterociclo de 4 - 10 miembros, en donde el carbociclo y heterocíclico se sustituyen opcionalmente con alquilo C₁₋₆, cicloalquilo C₃₋₆, -(CH₂)ₙ-C(=O)O-alquilo C₁₋₄, -(CH₂)ₙ-O-alquilo C₁₋₄ y =O; n, en cada caso, se selecciona de 0, 1, 2, 3 y 4; y; p, en cada caso, se selecciona de 0, 1 y 2.
ARP120102879A 2011-08-05 2012-08-07 Ligadores p1 ciclicos como inhibidores del factor xia AR088423A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161515404P 2011-08-05 2011-08-05

Publications (1)

Publication Number Publication Date
AR088423A1 true AR088423A1 (es) 2014-06-11

Family

ID=46964007

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102879A AR088423A1 (es) 2011-08-05 2012-08-07 Ligadores p1 ciclicos como inhibidores del factor xia

Country Status (8)

Country Link
US (2) US8901115B2 (es)
EP (2) EP3070087B1 (es)
JP (1) JP6113727B2 (es)
CN (2) CN105294701B (es)
AR (1) AR088423A1 (es)
ES (2) ES2563445T3 (es)
TW (1) TW201319068A (es)
WO (1) WO2013022814A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020528B1 (ru) 2010-02-11 2014-11-28 Бристол-Майерс Сквибб Компани Макроциклы в качестве ингибиторов фактора xia
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
RS56168B1 (sr) 2011-10-14 2017-11-30 Bristol Myers Squibb Co Supstituisana jedinjenja tetrahidroizohinolina kao inhibitori xia faktora
EP2766347B1 (en) 2011-10-14 2016-05-04 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
HUE032622T2 (en) * 2012-08-03 2017-10-30 Bristol Myers Squibb Co Dihydropyridone P1 as factor XIA inhibitors
DK2882734T3 (en) * 2012-08-03 2017-01-30 Bristol Myers Squibb Co DIHYDROPYRIDON AS FACTOR-XIA INHIBITORS
LT2906551T (lt) 2012-10-12 2018-04-25 Bristol-Myers Squibb Company Faktoriaus xia kristalinės formos
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
US9809545B2 (en) 2013-03-27 2017-11-07 Merck Sharp & Dohme Corp. Factor XIa inhibitors
NO2760821T3 (es) * 2014-01-31 2018-03-10
EP3392249B1 (en) * 2014-01-31 2021-08-25 Bristol-Myers Squibb Company Macrocycles with heterocyclic p2' groups as factor xia inhibitors
US9663527B2 (en) 2014-02-11 2017-05-30 Merck Sharp & Dohme Corp. Factor XIa inhibitors
WO2015123091A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Factor xia inhibitors
WO2015123093A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Factor xia inhibitors
US10093683B2 (en) 2014-04-22 2018-10-09 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3180317B1 (en) 2014-07-28 2021-04-14 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
EP3189047B1 (en) 2014-09-04 2018-12-26 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
NO2721243T3 (es) 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
WO2016093285A1 (ja) * 2014-12-10 2016-06-16 小野薬品工業株式会社 ジヒドロインドリジノン誘導体
WO2016205482A1 (en) * 2015-06-19 2016-12-22 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors
WO2017019819A1 (en) 2015-07-29 2017-02-02 Bristol-Myers Squibb Company Factor xia macrocyclic inhibitors bearing alkyl or cycloalkyl p2' moieties
ES2871111T3 (es) 2015-07-29 2021-10-28 Bristol Myers Squibb Co Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático
WO2017074833A1 (en) 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
AU2016344476B2 (en) * 2015-10-29 2020-08-13 Merck Sharp & Dohme Llc Factor XIa inhibitors
KR20180117156A (ko) 2016-03-02 2018-10-26 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제 활성을 갖는 디아미드 마크로사이클
EP3500556B1 (en) 2016-08-22 2023-08-02 Merck Sharp & Dohme LLC Pyridine-1-oxide derivatives and their use as factor xia inhibitors
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2018133793A1 (zh) * 2017-01-18 2018-07-26 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
WO2019011166A1 (zh) * 2017-07-14 2019-01-17 四川科伦博泰生物医药股份有限公司 大环酰胺化合物及其药物组合物和用途
ES2942214T3 (es) * 2018-04-17 2023-05-30 Univ Michigan Regents Inhibidores de la función plaquetaria y procedimientos de utilización de los mismos
CA3136861A1 (en) 2019-04-16 2020-10-22 Medshine Discovery Inc. Macrocyclic derivatives acting as xia factor inhibitor
US20220281868A1 (en) * 2019-07-23 2022-09-08 Medshine Discovery Inc. Macrocyclic derivatives as factor xia inhibitors
CN115490708A (zh) * 2021-06-18 2022-12-20 苏州亚盛药业有限公司 磺酰胺类大环衍生物及其制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
JPH0987280A (ja) * 1995-09-28 1997-03-31 Yamanouchi Pharmaceut Co Ltd オキソピペラジン誘導体又はその塩
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
CA2383008A1 (en) 1999-06-14 2000-12-21 Amanda Jane Lyons Compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2002322802A1 (en) * 2001-07-27 2003-02-17 Merck And Co., Inc. Thrombin inhibitors
PL204263B1 (pl) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Pochodna 1H-pirazolo[3,4-c]pirydyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
JP5236293B2 (ja) 2005-01-13 2013-07-17 ブリストル−マイヤーズ スクイブ カンパニー Ｘｉａ因子阻害剤としての置換ビアリール化合物
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
NZ568595A (en) 2005-12-14 2010-04-30 Bristol Myers Squibb Co Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
CN101341124A (zh) 2005-12-14 2009-01-07 布里斯托尔-迈尔斯斯奎布公司 可用作丝氨酸蛋白酶抑制剂的6元杂环
US8466295B2 (en) 2005-12-14 2013-06-18 Bristol-Myers Squibb Company Thiophene derivatives as factor XIa inhibitors
TW200745062A (en) * 2005-12-23 2007-12-16 Bristol Myers Squibb Co Macrocyclic factor VIIA inhibitors useful as anticoagulants
CN101389613B (zh) * 2005-12-23 2011-10-12 布里斯托尔-迈尔斯.斯奎布公司 用作抗凝血药的大环凝血因子viia抑制剂
JP5342450B2 (ja) 2006-12-15 2013-11-13 ブリストル−マイヤーズ スクイブ カンパニー 第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
EP2152664B1 (en) 2007-06-13 2014-09-03 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
EP2070899A1 (en) 2007-12-14 2009-06-17 F. Hoffmann-La Roche Ag Deprotection of N-BOC compounds
ES2380648T3 (es) * 2008-03-13 2012-05-17 Bristol-Myers Squibb Company Derivados de piridazina como inhibidores del factor XIA
EA020528B1 (ru) 2010-02-11 2014-11-28 Бристол-Майерс Сквибб Компани Макроциклы в качестве ингибиторов фактора xia
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
EP2766347B1 (en) 2011-10-14 2016-05-04 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
RS56168B1 (sr) 2011-10-14 2017-11-30 Bristol Myers Squibb Co Supstituisana jedinjenja tetrahidroizohinolina kao inhibitori xia faktora
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
HUE032622T2 (en) 2012-08-03 2017-10-30 Bristol Myers Squibb Co Dihydropyridone P1 as factor XIA inhibitors
DK2882734T3 (en) 2012-08-03 2017-01-30 Bristol Myers Squibb Co DIHYDROPYRIDON AS FACTOR-XIA INHIBITORS
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
LT2906551T (lt) 2012-10-12 2018-04-25 Bristol-Myers Squibb Company Faktoriaus xia kristalinės formos
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors

Also Published As

Publication number Publication date
JP2014521700A (ja) 2014-08-28
CN103702999B (zh) 2015-11-25
CN105294701B (zh) 2017-10-24
US9108981B2 (en) 2015-08-18
ES2563445T3 (es) 2016-03-15
EP2739625A1 (en) 2014-06-11
US20150057262A1 (en) 2015-02-26
EP3070087A1 (en) 2016-09-21
ES2733096T3 (es) 2019-11-27
EP2739625B1 (en) 2016-01-20
CN105294701A (zh) 2016-02-03
TW201319068A (zh) 2013-05-16
US20140163002A1 (en) 2014-06-12
EP3070087B1 (en) 2019-04-10
US8901115B2 (en) 2014-12-02
WO2013022814A1 (en) 2013-02-14
CN103702999A (zh) 2014-04-02
JP6113727B2 (ja) 2017-04-12

Similar Documents

Publication Publication Date Title
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR108875A1 (es) COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
AR088748A1 (es) Macrociclos como inhibidores del factor xia
AR120338A1 (es) Piridazinonas como inhibidores de parp7
AR106595A1 (es) COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
AR108396A1 (es) Compuestos heterocíclicos como inmunomoduladores
AR101208A1 (es) Espirocicloheptanos como inhibidores de rock
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
AR100059A1 (es) Compuestos útiles como inmunomoduladores
AR091023A1 (es) Inhibidores del nampt
AR100975A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR094313A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR096788A1 (es) Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
AR088781A1 (es) Compuestos antimicrobianos y metodos para prepararlos y utilizarlos
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR103990A1 (es) Ureas cíclicas como inhibidoras de rock
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR094929A1 (es) Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2